FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Vashington,	D.C. 20549	
-------------	------------	--

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Wong Hing C				2. Issuer Name and Ticker or Trading Symbol HCW Biologics Inc. [HCWB]							5. I (Ch	Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
													X Director				
(Last)	(F	irst)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year)								X below)	(give title	belov	(specify v)	
C/O HCW BIOLOGICS INC					09/08/2021							Cl	Chief Executive Officer				
2929 N. COMMERCE PARKWAY																	
					4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable				
(Street)												Lin	,		D		
MIRAM	AR FI	L	33025											,	Reporting Per than One Re		
,													Person		than One Rep	lorung	
(City)	(S	tate)	(Zip)														
		Ta	ble I - Non-	-Derivat	ive S	ecuritie	s Acq	uired, I	Disp	osed c	of, or Be	neficial	y Owned				
Date			2. Transact Date (Month/Day	Execution Date,		Code (II	Transaction Disposed Of (D) (Instr. 3, 4 Code (Instr.				Beneficia Owned F	s Illy ollowing	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership			
								Code	v	Amount	Amount (A) or (D)		Transacti	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	ate Execution Da	Code	saction (Instr.	Derivative		6. Date Exercisal Expiration Date (Month/Day/Year		of Securities		ties ig e Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s	Owners Form: Direct (I or Indire (I) (Instr	Beneficial Ownership ct (Instr. 4)	
				Code	v	(A)		Date Exercisable		xpiration ate	Title	Amount or Number of Shares		(Instr. 4)	(5)		
Stock Option (Right to Buy)	\$4.31	09/08/2021		A		800,000		(1)	09	9/07/2031	Common Stock	800,000	\$0.00	800,000	D D		

Explanation of Responses:

1. The option will vest as follows: 20% will vest on September 8, 2022, 20% will vest on September 8, 2023, 25% will vest on September 8, 2024 and 35% will vest on September 8, 2025.

Remarks:

/s/ Nicole Valdivieso, as Attorney-in-Fact for Hing C.

09/10/2021

Wong

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.